JUL 10, 2020 8:29 AM PDT

Injection 66% Better than Daily Pill to Prevent HIV

WRITTEN BY: Annie Lennon

Pharmaceutical company ViiV Healthcare has announced that its long-lasting, injectable drug, cabotegravir, is more effective than Truvada, Gilead Sciences' daily oral tablets, at preventing HIV. 

Until now, Truvada has been seen as the frontline measure after condoms to prevent HIV. With the results from the most recent trial, however, this may change. 

The results come from a randomized, multi-center, double-blind Phase IIb/III clinical trial. Participants included 4, 566 men and transgender women who have sex with men and were HIV-negative at the beginning of the study.

Among the 52 participants who acquired HIV throughout the trial, 13 were in the study group who received cabotegravir alongside placebo daily oral tablets, and 39 were in the group receiving daily oral Truvada with placebo injections. 

Thus, while 1.22% of those in the Truvada group acquired HIV, just 0.41% of those in the cabotegravir group acquired the virus. As such, the researchers concluded that the injection, given once every two months, was 66% more effective at preventing HIV than Truvada. 

"These data are truly ground-breaking, demonstrating that long-acting injectable cabotegravir dosed every two months is superior to daily oral FTC/TDF at preventing HIV in at-risk men and transgender women who have sex with men." says Kimberly Smith, head of research and development at ViiV Healthcare Research. 

"This advancement has the potential to be a game-changer for HIV prevention, offering an option with very high rates of effectiveness and the convenience of reduced dosing from daily to just six times per year."

While nausea was more common among those taking FTC/TDF during the trial, the most common side effects for those on cabotegravir were injection site reactions, hypertension, and fever. 

Cabotegravir is now being assessed for safety and efficacy for HIV prevention in over 3,000 sexually active women in several African countries. 

 

Sources: Clinical Trials ArenaNational Institutes of Health

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
OCT 01, 2020
Cancer
Understanding in vivo Metabolomics: C13 Isotope Studies
OCT 01, 2020
Understanding in vivo Metabolomics: C13 Isotope Studies
One key to understanding cancer metabolomics lies in the ability to accurately replicate the natural environment of the ...
OCT 03, 2020
Cannabis Sciences
Cannabis Compound Prevents Colon Cancer in Mice
OCT 03, 2020
Cannabis Compound Prevents Colon Cancer in Mice
Second only to skin cancer, colon cancer is the most common cancer diagnosed in both men and women in the US. Now, resea ...
OCT 14, 2020
Immunology
Self-Healing Microcapsules Make Promising Leukemia Vaccines
OCT 14, 2020
Self-Healing Microcapsules Make Promising Leukemia Vaccines
Leukemia is a cancer affecting tissues in the body that produce blood cells, including the bone marrow and the lymphatic ...
OCT 21, 2020
Drug Discovery & Development
Experimental Vaccine Shows Promise in Halting Alzheimer's
OCT 21, 2020
Experimental Vaccine Shows Promise in Halting Alzheimer's
In a preclinical study, researchers from the Univerity of South Florida have found that a vaccine that targets neurotoxi ...
NOV 20, 2020
Drug Discovery & Development
Hyperbaric Oxygen Treatments Reverse Aging
NOV 20, 2020
Hyperbaric Oxygen Treatments Reverse Aging
Researchers from Israel have found that hyperbaric oxygen treatments (HBOT) in healthy aging adults can prevent blood ce ...
NOV 30, 2020
Microbiology
Common Antibiotic Could be Effective Zika Treatment
NOV 30, 2020
Common Antibiotic Could be Effective Zika Treatment
Zika virus cause a devastating epidemic in 2015, and led to the birth of hundreds of children that had congenital brain ...
Loading Comments...